top of page

Battle set for the European haemophilia B treatment market, says GlobalData

CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals in April 2016, according to an analyst with research and consulting firm GlobalData. Fenix Leung, DPhil, GlobalData’s Senior Analyst covering Oncology and Haematology, states that as the efficacy and safety of both Idelvion and Alprolix are considered to be very similar according to key opinion leaders interviewed by GlobalData, the time to market will be a key differentiator in determining the success of a drug in the haemophilia B market.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page